zyil1
Small moleculeexperimental
Clinical trial activity
6 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 28, 2020 (NCT04731324)
Timeline
Indications
Mechanism of action
NLRP3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07171983 | Phase 1 | Jan 22, 2026 | Bristol-Myers Squibb |
| NCT06086886 | Phase 1 | Oct 31, 2023 | Bristol-Myers Squibb |
| NCT05981040 | Phase 2 | Oct 27, 2023 | Zydus Discovery DMCC |
| NCT05186051 | Phase 2 | Jun 1, 2022 | Cadila Healthcare, Zydus Discovery DMCC |
| NCT04972188 | Phase 1 | Jul 12, 2021 | Cadila Healthcare, Zydus Discovery DMCC |
| NCT04731324 | Phase 1 | Dec 28, 2020 | Cadila Healthcare |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cadila Healthcare | For profit | 3 | 2 | 2 | 2020 |
| Zydus Discovery DMCC | For profit | 3 | 2 | 2 | 2021 |
| Bristol-Myers Squibb | For profit | 2 | 2 | 1 | 2023 |
3 organizations
Page 1 / 1